Nifedipine in Congenital Hyperinsulinism - A Case Report.
Journal of Clinical Research in Pediatric Endocrinology
© Journal of Clinical Research in Pediatric Endocrinology, 2015. Published by Galenos Publishing. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Congenital hyperinsulinism (CHI) is the commonest cause of persistent hypoglycemia in neonates. Diazoxide is the first-line drug in its treatment, but the more severe cases are usually diazoxide-resistant. Recessive ABCC8 and KCNJ11 mutations are responsible for most (82%) of the severe diazoxide-unresponsive CHI. Oral nifedipine has been effective in isolated cases of CHI. Successful treatment of diazoxide-unresponsive CHI with a combination of octreotide and nifedipine has been reported in a single isolated case so far. We report here a case of diazoxide-resistant CHI due to homozygous ABCC8 nonsense mutation. In this case, hypoglycaemia uncontrolled by pancreatectomy and octreotide alone showed a good response to a combination of nifedipine and octreotide. Octreotide was tapered off by one year age and thereafter the child is euglycaemic on oral nifedipine alone. Continuous glucose monitoring sensor was used as an aid to monitor glycaemic control and was found to be a safe and reliable option reducing the number of needle-pricks in small children.
This is the final version of the article. Available from Galenos Yayınevi via the DOI in this record.
Vol. 7, No. 2, pp. 151-154
Place of publication